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Background: This article is aimed to assess quantitatively metamorphopsia using M-charts in patients suffering
from wet age-related macular degeneration (AMD) treated with the intravitreal bevacizumab injections and to
compare the results with traditional Amsler grid and ocular coherence tomography (OCT).
Methods: Thirty-six patients diagnosed with wet AMD were examined one day before and one month after the
intraocular injection of bevacizumab. Horizontal and vertical metamorphopsia scores using M-charts, distance visual
acuity, Amsler test and OCT were performed at each visit. Additionally, 23 healthy subjects were examined as a
control group.
Results: The rate of metamorphopsia detection was 89% with M-charts and 69% with Amsler test. The horizontal
metamorphopsia score improved in 22 patients, the vertical metamorphopsia score improved in 16 patients, the
Amsler grid results improved in 6 patients, visual acuity improved in 17 patients. There was no correlation between
the degree of metamorphopsia and the visual acuity or the central retinal thickness (CRT). The specificity of both
the M-charts and Amsler grid was 100%.
Conclusions: The rate of metamorphopsia detection in wet AMD patients was better with M-charts than with Amsler
grid. M-charts may be used in the assessment of efficacy of treatment with intravitreal bevacizumab injections as another
outcome measure, moreover they can be used even at home for the self-assessment. M-charts provide additional
information concerning the visual function, independent of the visual acuity, CRT and morphological changes in OCT.
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Metamorphopsia is a hallmark sign in patients with
macular diseases and can be defined as a deformation of
seen straight lines due to the displacement of photorecep-
tors. Age-related macular degeneration (AMD) is the most
common macular disease affecting millions of aged people
in the developed countries [1]. The most effective method
of treating wet AMD is currently the anti-vascular endothe-
lial growth factor (VEGF) – bevacizumab or ranibizumab
[1]. With introduction of new treatment modalities preserv-
ing macular function, non-invasive and quick assessment of
efficacy of the treatment is crucial for diagnostics of AMD.* Correspondence: katarzynanowomiejska@mailcity.com
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distribution, and reproduction in any mediumFluorescein angiography may be associated with serious
complications [2], hence it has been replaced in clinical
practice by Optical Coherence Tomography (OCT). OCT
is proving to be an accurate and reproducible tool for quali-
tative and quantitative assessment of the macular structure
[3]. For assessment of the visual function, visual acuity and
Amsler grid have been the gold standard.
The Amsler grid, consisting of evenly spaced horizontal
and vertical lines, has been widely used since 1947 to test
the metamorpho psia [4]. The Amsler grid is very cheap,
straightforward and easily understood by the patient.
However, it also produces high false negative rate [5].
Moreover, this test does not allow for the quantification of
the severity of metamorphopsia; thus, it is difficult toentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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effectiveness of treatment with anti-VEGF agents.
The M-chart (Inami Co., Tokyo, Japan) is a diagnostic
tool developed by Matsumoto [6] to quantify the degree
of metamorphopsia in patients with macular diseases.
The usefulness of M-charts has been already shown in
patients with epiretinal membranes [7,8], macular holes
[9] and branch retinal vein occlusion [10].
The aim of this study was to evaluate metamorphopsia
quantitatively, using the M-charts in patients suffering
from wet AMD before and after bevacizumab injection
and to compare the results with traditional Amsler grid
and OCT results.
Methods
Thirty-six patients (12 men, 24 women) were selected
prospectively from the retinal out-patient clinic of the
Department of General Ophthalmology in Lublin,
Poland. The study was approved by the independent
ethics committee and performed in accordance with
the Declaration of Helsinki. Written informed consent
was taken from each participant after the explanation
of the nature of the study had been provided. Patients
with wet AMD, diagnosed by means of OCT and with
the best corrected visual acuity, better than or equal
to 0.1, were included in the study. The exclusion criteria
were diseases affecting the retina, other than AMD, such
as glaucoma, amblyopia, strabismus, prior intraocular
surgery, refracting error greater than ±5D.
The baseline examination and the follow-up examination
performed one month later included a complete ophthal-
mological examination (slit lamp examination, applanation
tonometry, dilated funduscopy) and OCT (Cirrus, Zeiss).Figure 1 Example of the result of vertical (VM = 0.4°) (left) and horizo
subject one after another (starting with the solid line - 0°), until the subject
was very distorted, following lines with larger dot intervals were recognized
vertical metamorphopsia score is 0.4°. After rotating M-charts 90° into the h
was recognized as straight, thus the horizontal M-chart score is 0.5°.Visual function testing included: best corrected distance
visual acuity test using Snellen charts and the standard
Amsler chart (black grid on a white background) with near
correction and undilated pupils. The M-charts were used
to assess both the horizontal and vertical metamorphopsia
scores. The M-charts consist of 19 dotted (dot size is 0.1°)
lines with dot intervals ranging from 0.2° to 2.0° of visual
angle. In the centre of each line, there is a fixation point of
0.3°. The examination is performed at the distance of
30 cm with appropriate near correction. Dotted lines with
interval changes from fine to coarse are printed on the
following paper pages and are shown to the patients one
after another.
The examiner presents consecutive dotted lines,
starting with a solid line (0°) and the patient has to state
whether the presented line is distorted or not. If the
patient recognizes the dotted line as being straight, its
visual angle is considered to be the metamorphopsia
score (Figure 1). M-charts are presented in vertical and
horizontal direction (having been rotated by 90°).
As the quantitative parameter of the structural examin-
ation the central retinal thickness (CRT) was used. CRT is
the distance between the anterior (internal limiting mem-
brane) and posterior (retinal pigment epithelium) highly
reflected boundaries of the retina. Additionally, OCT re-
sults were assessed qualitatively and classified as serous
pigment epithelial detachment, subretinal fluid, cystic
retinal oedema or combination of these conditions.
For the present study, one eye of each patient was
taken into consideration. The average age of examined
patients was 72.0 years (range 50–87 years). The median
visual acuity was 0.3 (range 0.1–0.7). All patients under-
went intravitreal injection of bevacizumab (1.25 mg) andntal (HM = 0.5°) (right) M-chart. Dotted lines are shown to the
recognizes the line as being straight. In this case the vertical solid line
as less distorted. Line 0.4° was recognized as straight, thus the
orizontal direction the same procedure was perfomed, until line 0.5°
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The injections were performed in a standard manner via
pars plana in an operating room [11].
Additionally, 23 age-matched healthy subjects (13 men,
10 women) without retinal pathology were examined as a
control group. The median visual acuity was 1.0 (range
0.8–1.0), the average age 68.3 years (range 52–90 years).
The average CRT was 265.5 μm (95% CI 256–275 μm).
Statistical analysis
The Amsler test was considered positive if any blurred
lines were reported by the patient. The M-chart result
was considered positive if the metamorphopsia score
was more than 0° (0.2–2.0°). If it was 0°, it was considered
as negative. This assessment was done in regard to vertical
and horizontal charts separately and for both methods to-
gether – it was considered as positive if one of them was
positive, and negative if both were negative. The medians
of the vertical and horizontal metamorphopsia score as
well as distance visual acuity and CRT before and after
bevacizumab injection were compared using the Wilcoxon
test. The Spearman’s correlation coefficient was used to
assess the relationship between the metamorphopsia,
visual acuity and the CRT. Mann–Whitney test was used
to assess the relationship between vertical and horizontal
M-chart and quantitative results of OCT.
Results
The rate of the detection of the metamorphopsia (percent-
age of positive results) of vertical M-chart was 75% before
the injection and 56% after the injection, horizontal M-
charts - 84% and 56%, both together - 89% and 64%, theFigure 2 Medians of the vertical - VM (left) and horizontal - HM (right
the bevacizumab injection.sensitivity of Amsler test - 69% and 58% respectively. The
vertical metamorphopsia score decreased after the
bevacizumab injection in 16 patients (0.2° average); it in-
creased in 7 patients (mean 0.1°); there was no change in
13 patients. The horizontal metamorphopsia score de-
creased in 22 patients (0.2° average), increased in 3 pa-
tients (0.1° average), there was no change in 11 patients.
The median of the vertical metamorphopsia score was
0.25° (range 0–2.0) before the bevacizumab injection
and 0.2° (range 0–1.7) after the bevacizumab injection
(p = 0.12). The median of the horizontal metamorphopsia
score was 0.3° (range 0–2.0) before the bevacizumab injec-
tion and 0.2° (range 0–2.0) after the bevacizumab injection
(p = 0.004) (Figure 2).
The Amsler grid results improved in 6 patients, deterio-
rated in 2 patients and remained the same in 28 patients.
The visual acuity improved in 17 patients, remained the
same in 13 patients and deteriorated in 6 patients. The me-
dian distance visual acuity was 0.3 before the bevacizumab
injection and 0.35 after the injection (p = 0.008).
The median CRT in OCT was 343.5 μm (95% CI 305.8–
381.4 μm) before the injection and 285.4 μm (95% CI
250–320 μm) after the injection (p < 0.01). CRT improved
in 33 patients. No relationship was found between the ver-
tical and horizontal metamorphopsia score and the visual
acuity (R = −0.2 and R = −0.06, respectively) or with CRT
(R = −0.14 and R = −0.001, respectively). The results of
OCT were as follows: subretinal fluid and intraretinal
cysts in 15 cases, intraretinal cysts only in 13 cases, pig-
ment epithelium detachment in 5 cases, subretinal fluid
only in 2 cases and pigment epithelium detachment with
subretinal fluid in 1 case. There were no statistically) metamorphopsia score obtained with M-charts before and after
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M-charts between above mentioned groups of patients.
All the healthy age-matched subjects revealed no
metamorphopsia either in Amsler test or in vertical and
horizontal M-charts (median 0°), thus the specificity of
both the M-charts and Amsler grid was 100%.Discussion
The present study is the first investigation comparing
the results of the M-charts and the Amsler grid with
OCT results in the assessment of metamorphopsia in
patients with wet AMD treated with the intravitreal
bevacizumab injections.
It has been demonstrated that the M-charts may be used
as a diagnostic tool in the detection of metamorphopsia in
AMD patients. The rate of metamorphopsia detection in
patients classified to the bevacizumab injection was higher
with the M-charts (89%) than with Amsler test (69%).
Thus, it seems that the M-charts are superior to the
Amsler grid in detecting metamorphopsia in patients with
wet AMD. In the current study, it has also been shown
that with the M-charts, it is possible to monitor quantita-
tively the changes in the degree of metamorphopsia over
time. The median of the vertical metamorphopsia score
decreased from 0.25° to 0.2° after the bevacizumab injec-
tion (not significant) and the median of the horizontal
metamorphopsia score decreased from 0.3° to 0.2° (signifi-
cant). The improvement in the meatmorphopsia score
after the injection suggests that the M-charts can be used
in the assessment of the effectiveness of treatment with
intravitreal injections. The M-charts have already been
used in the evaluation of the effectiveness of vitrectomy in
patients with macular holes [9,12]. Arimura and colleagues
have shown that after vitrectomy visual acuity improved
in 14 of 22 patients and metamorphopsia scores improved
in 19 of 22 patients [9].
The best current practice involves using the Amsler
charts for detecting and monitoring metamorphopsia in
AMD. However, it has already been reported that the
Amsler test has poor sensitivity [12]. The sensitivity of
the Amsler chart in AMD varies between 9% in early
stages to 34% in choroidal neovascularisation [13]. In a
study comparing the Amsler grid with microperimetry,
the sensitivity of the Amsler chart was only 56%; in pa-
tients with small scotomas, the false negative rate was
found to be 77% [14]. There are many possible explana-
tions for this high false-negative rate. Firstly, the filling-in
phenomenon across pathological scotomas [14]; secondly,
the use of a preferred retinal locus away from the scot-
oma boundary [15]; moreover, probably, the averaging
of crowded stimuli [16]. Moreover, the results of the
Amsler charts are only descriptive; they are neither
precise nor reproducible. Thus the Amsler chart alonedoes not seem to be sufficient for the metamorphopsia
detection and for monitoring the changes over time.
The M-charts provide more information than the
Amsler chart in regard to the horizontal and vertical lines.
It has been found that the decrease of metamorphopsia
was significant for horizontal lines only. The difference
between horizontal and vertical metamorphopsia has been
already observed by Amsler [17]. Matsumoto found [7]
that metamorphopsia is more severe in horizontal than in
vertical lines in patients with epiretinal membranes. He
proposed that the abovementioned fact may be explained
by the differences of human visual sensitivities between
horizontal and vertical visual fields [18].
Up to now, some modifications have been made to the
traditional Amsler chart, such as threshold Amsler test-
ing with cross-polarizing filters reducing the luminance
of the grid [19]. It has been shown that it increased the
detection rate in patients with diabetic retinopathy [20].
An alternative test used as a replacement for the Amsler
grid is the Macular Computerized Psychophysical Test
introduced in 2003 [13]. In this test, a virtual line com-
posed of dots (white dots on a black background, max-
imal contrast on the computer screen) is flashed across
different macular loci to a perifoveal radius of 7 degrees.
The patient is asked to report any blurring or gaps
within the line. The commercial form of this method is
known as the Preferential Hyperacuity Perimetry (PHP).
In this test, a single straight dotted line with a few dots
out of alignment is flashed across different macular loci
over a macular field of 14° × 14°. The patient uses a sty-
lus to touch the screen where he had experienced a dis-
tortion in the line. Any distortion perceived by the
patient is automatically recorded and analyzed, and a
macular map showing the area of distortion and the in-
tensity of metamorphopsia is displayed. The authors
reported the superiority of this test over the Amsler grid
in patients with AMD [21]. PHP has been also used in
the assessment of metamorphopsia in AMD patients
treated with ranibizumab [22]. The improvement of
metamorphopsia score was observed after 6 months
after the injection. In a study comparing PHP with the
M-charts published by Arimura [23], the M-charts
showed better sensitivities than PHP in both ERM (89%
vs. 42%) and AMD (74% vs. 68%). However, PHP is com-
plicated and rather expensive, thus it is not widely used
in clinical practice.
In order to be deemed trustworthy, a diagnostic
method should have an acceptable level not only of sen-
sitivity, but also of specificity. In the current study, no
healthy person has seen metamorphopsia either with the
M-charts or the Amsler test. Thus, the specificity of
both methods was 100% and there were no false-positive
results. However, in a study performed by Loewenstein,
the Amsler chart has been shown to indicate the
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without any scotoma [13]. In a study comparing Amsler
grid with PHP, there was a better specificity of PHP - it
was 100% vs. 71% with the Amsler grid in healthy
controls [23].
Interestingly, no significant relationship was found
between the degree of metamorphopsia and the visual
acuity in our group of patients with AMD. The same
finding was described by Matsumoto [6] in a group of
patients with metamorphopsia due to epiretinal mem-
brane. Thus, metamorphopsia seems to be independent
of the visual acuity, being another clinical aspect of the
visual function. Metamorphopsia is not a simple symp-
tom and it consists of several kinds of components. In
particular, there are several kinds of frequency compo-
nents of distortion in metamorphopsia. Moreover, in the
present study, no relationship was found between the
degree of metamorphopsia and CRT as well as morpho-
logical changes in OCT. A longer follow-up is needed to
determine if M-charts can be used to identify the cases with
complete resolution of metamorphopsia, the cases with
persistent metamorphopsia and the cases with recurrence
of metamorphopsia associated with CNV recurrence.
Conclusions
The study concludes that the M-charts are a simple,
fast, easy and cheap method for the quantification of
metamorphopsia that can be used even at home for self-
assessment. The present research has shown that the
M-charts are superior to the traditional Amsler charts,
as they detect metamorphopsia even if the Amsler chart
is normal. The M-charts provide additional information
in regard to the visual function independent from visual
acuity and OCT results and can be used in the quantita-
tive assessment of the progression of metamorphopsia
in patients suffering from wet AMD treated with
bevacizumab injections.
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